This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Related articles  • Similar articles in this journal  Topic Collections  • Men's Health  • Prostate Disease  • Oncology  • Alert me on articles by topic

Siam Oottamasathien, MD; E. David Crawford, MD

Arch Intern Med. 2003;163:665-666.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

THERE IS certainly a heated controversy surrounding prostate cancer screening with PSA and DRE. Dr Hoffman makes a fair argument against screening, but the key issue is that we as physicians need to routinely discuss and educate our patients to the risks and benefits of screening. Once again, knowledge is power.

Dr Hoffman is correct that there is no good method to prevent prostate cancer, but it is not entirely true that men with advanced cancers can be treated only from a palliative standpoint. Traditionally, hormone therapy has been used in prostate cancer with locally advanced disease and/or metastatic disease. Currently, several trials indicate a survival advantage with the use of early hormonal intervention for prostate cancer. For example, the Medical Research Council study¹ randomized patients with nonmetastatic locally advanced disease (stage T3) to 1 of 2 study arms: (1) early, lifelong hormonal . . . [Full Text of this Article]

RELATED ARTICLES

Should Routine Screening for Prostate-Specific Antigen Be Recommended?
Siam Oottamasathien and E. David Crawford
Arch Intern Med. 2003;163(6):661-663.
EXTRACT | FULL TEXT  

An Argument Against Routine Prostate Cancer Screening
Richard M. Hoffman
Arch Intern Med. 2003;163(6):663-665.
EXTRACT | FULL TEXT  

Rebuttal by Dr Hoffman
Richard M. Hoffman
Arch Intern Med. 2003;163(6):666.
EXTRACT | FULL TEXT